The Impact of Biosimilar Competition in Europe
The ‘Impact of Biosimilar Competition in Europe’ report describes the effects of biosimilars on price, volume and
The report consists of observations on competitive markets, and a set of Key Performance Indicators (KPIs) to monitor the impact of biosimilars in 23 European markets.
This series of reports has been a long-standing source of information on the status of the biosimilar market. This year, we deliver more granular insight into the categorisation of biological medicines over time, and additional data (to June 2020 MAT) to give a broader view than previous reports, and take into account the impact of the COVID-19 pandemic.
The major observations in this white paper cover: the savings potential, usage of biological medicines, originator defence strategies, biosimilar policies, and the future opportunity due to biologic loss of exclusivity.